- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02242838
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
September 16, 2014 updated by: Boehringer Ingelheim
Post-Marketing Surveillance of Micardis® (Telmisartan) Special Drug Use-results Survey on Long-term Treatment
The primary objective of this survey is to prospectively investigate safety and efficacy in patients with hypertension treated with telmisartan in proper use in medical practice over a long period
Study Overview
Study Type
Observational
Enrollment (Actual)
6336
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Hypertension patients without telmisartan treatment are selected at medical institutions
Description
Inclusion Criteria:
- Patients with hypertension
Exclusion Criteria:
Patients with the following conditions
- Patients with a history of hypersensitivity of this product
- Women in pregnancy (included the possibility of pregnancy)
- Patients with severe biliary obstructive disorders or severe hepatic insufficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hypertensive patients
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse drug reactions
Time Frame: up to 1 year
|
up to 1 year
|
|
Incidence of adverse drug reactions
Time Frame: up to 1 year
|
classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology
|
up to 1 year
|
Change in Mean systolic blood pressure (SBP)
Time Frame: up to 1 year
|
up to 1 year
|
|
Change in Mean diastolic blood pressure (DBP)
Time Frame: up to 1 year
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall assessment of efficacy by investigator on 4-point scale
Time Frame: at 3 month, after 1 year
|
at 3 month, after 1 year
|
Change in pulse rate
Time Frame: up to 1 year
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2003
Primary Completion (Actual)
September 1, 2006
Study Registration Dates
First Submitted
September 16, 2014
First Submitted That Met QC Criteria
September 16, 2014
First Posted (Estimate)
September 17, 2014
Study Record Updates
Last Update Posted (Estimate)
September 17, 2014
Last Update Submitted That Met QC Criteria
September 16, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 502.500
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Telmisartan
-
Emory UniversityNational Institute on Aging (NIA)Completed
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedDiabetic NephropathiesJapan
-
Boehringer IngelheimCompleted
-
Laboratorio Elea Phoenix S.A.Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBACompleted